Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
about
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersApproaches to modernize the combination drug development paradigmMaximising the potential of AKT inhibitors as anti-cancer treatmentsAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiationBlocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.Lipid phosphatase SHIP2 functions as oncogene in colorectal cancer by regulating PKB activation.Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.Targeting leiomyomas with all-trans-retinoic acid at phosphoinositide 3-kinase pathway suppression: Effective roles of β-catenin and of signaling interactions.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Selumetinib in the treatment of non-small-cell lung cancer.Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.AKT in cancer: new molecular insights and advances in drug development.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.Structure, signaling and the drug discovery of the Ras oncogene protein.Small molecule drugs with immunomodulatory effects in cancer.Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.MEK inhibitors for the treatment of NRAS mutant melanoma
P2860
Q26781362-37FBD30A-FD60-44D1-B362-4A393F74D195Q28072074-EC1179B3-3041-450B-939D-093DDAE305EBQ28072254-3C0A65C8-8766-462B-B831-13441DD85F87Q28080599-2210EFC0-85BC-4363-8594-35EB663EA6E6Q36117718-DBD10874-1877-4DD2-802E-B6269B5BB357Q36771749-C36DDBD2-0E67-4EDF-ABF4-069E8B7349D2Q37684405-195CB928-3DDC-4808-AD49-CD895C0B117DQ37687424-FAB90559-EF49-45E7-B61E-E789C1A2B5DCQ38383457-44E58A76-2404-43F8-A561-BB8786B86F00Q38733117-230C71B6-8F62-49A6-9FB8-8A5A3E66EF26Q38761092-244C1D13-69D4-4B09-A49D-1767B5860AA5Q38786707-55A946ED-8B27-4A4A-9CAF-4673E0EAC90EQ38794338-134A91F3-EB50-4C18-A2D1-330509CEC72BQ38836927-D6AA4FFC-E20D-4C4E-9157-4926AFD0C626Q38841033-105C40E1-C030-4CA5-A5DA-422A64DA2CC7Q38846044-149FE62B-1C44-4E09-9496-628884E34172Q38941928-4FCACEA9-082C-47B0-8E6D-CA7169964444Q39270291-85723C55-ACC9-40C4-AC74-B2F2B0A1786AQ42353910-16BEDAE4-6FFE-404B-96EC-FD27A7371808Q45814047-03138E58-31B7-4E6D-A5F2-CB4DBB4B34FCQ47122504-AF8A5CE0-D047-44F2-8BB2-92DB82F5DF98Q51736090-5D0A354E-EBB3-4FAD-A523-388803ACA2CBQ55332287-F47A8F62-FE38-4557-A39C-E929CC0CEF5CQ56889985-4605165E-6486-4E55-906B-D15F43C9B592
P2860
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Biomarker-driven phase 2 study ...... tients with colorectal cancer.
@en
type
label
Biomarker-driven phase 2 study ...... tients with colorectal cancer.
@en
prefLabel
Biomarker-driven phase 2 study ...... tients with colorectal cancer.
@en
P2093
P2860
P921
P1476
Biomarker-driven phase 2 study ...... tients with colorectal cancer.
@en
P2093
Giovanna Speranza
James H Doroshow
L Austin Doyle
Larry Rubinstein
Michael H Lam
Michelle Eugeni
Rachel Bishop
Robert J Kinders
Shivaani Kummar
P2860
P2888
P304
P356
10.1007/S10637-015-0212-Z
P577
2015-02-01T00:00:00Z
P6179
1014328773